

# Hyperbaric Oxygenation Modulates Vascular Reactivity to Angiotensin-(1-7) in Diabetic Rats: Potential Role of Epoxyeicosatrienoic Acids

---

Kibel, Aleksandar; Novak, Sanja; Ćosić, Anita; Mihaljević, Zrinka; Falck, John R; Drenjančević, Ines

Source / Izvornik: **Diabetes and Vascular Disease Research**, 2015, 12, 33 - 45

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1177/1479164114553424>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:239:597138>

Rights / Prava: [Attribution-NonCommercial 4.0 International](#)/[Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-11-07**




Repository / Repozitorij:

[Repository UHC Osijek - Repository University Hospital Centre Osijek](#)



# Hyperbaric oxygenation modulates vascular reactivity to angiotensin-(1-7) in diabetic rats: Potential role of epoxyeicosatrienoic acids

Diabetes & Vascular Disease Research  
2015, Vol. 12(1) 33–45  
© The Author(s) 2014  
Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav  
DOI: 10.1177/1479164114553424  
dvr.sagepub.com  


Aleksandar Kibel<sup>1</sup>, Sanja Novak<sup>1</sup>, Anita Cosic<sup>1</sup>, Zrinka Mihaljevic<sup>1</sup>,  
John R Falck<sup>2</sup> and Ines Drenjancevic<sup>1</sup>

## Abstract

Previously, a facilitating effect of hyperbaric oxygenation (HBO<sub>2</sub>) on aortic ring responses to angiotensin-(1-7) in healthy rats was reported, with epoxyeicosatrienoic acids (EETs) possibly playing an important role. The aim of this study was to assess whether HBO<sub>2</sub> exerts similar effects in diabetic rats and to further explore the role of specific cytochrome P450 (CYP) enzymes in changes induced by HBO<sub>2</sub>. Aortic relaxation to angiotensin-(1-7) was significantly higher in HBO<sub>2</sub> diabetic rats compared to control diabetic rats, while HBO<sub>2</sub> had no effect on angiotensin II contraction. N-methylsulphonyl-6-(2-propargyloxyphenyl)hexanamide inhibited the facilitation of angiotensin-(1-7) responses in HBO<sub>2</sub> rats, suggesting an important role of EETs in this modulation. mRNA expression of CYP2J3 and protein expression of CYP2C11 were significantly upregulated in HBO<sub>2</sub> diabetic rats, whereas CYP4A1, CYP4A2 and CYP4A3 mRNA and CYP2J3 protein expression was similar between groups. Mean arterial pressure, ferric reducing ability of plasma and Thiobarbituric Acid Reactive Substances levels and serum angiotensin-(1-7) concentrations were not significantly changed.

## Keywords

Hyperbaric oxygen therapy, angiotensin II, angiotensin-(1-7), epoxyeicosatrienoic acids

## Background

Hyperbaric oxygenation (HBO<sub>2</sub>) is every medical and experimental application of pure (100%) oxygen at a pressure level higher than atmospheric pressure.<sup>1</sup> Treatment with HBO<sub>2</sub> was traditionally used for a number of classic indications, such as gas gangrene, carbon monoxide poisoning, decompression sickness and others, but in recent years it has been shown to be beneficial in various conditions with vascular pathology.<sup>1</sup> The most clinically impressive effect of HBO<sub>2</sub> in that regard is its contribution to healing of ischaemic ulcerations in diabetic patients, but there are also other observed effects of HBO<sub>2</sub> therapy including neurological improvement after stroke, recovery from myocardial infarction and acute peripheral extremity ischaemia or reduction of atherosclerotic plaques.<sup>1–6</sup> Although these effects have been documented clinically and in experimental models, the exact mechanisms involved in the mediation of these HBO<sub>2</sub> actions are largely unknown, and studies regarding the influence of HBO<sub>2</sub> on vascular structure and function are scarce.<sup>1</sup> The effects of HBO<sub>2</sub> in pathologic conditions such as wound healing cannot be

simply explained with the compensation of the lack of oxygen and it has become clear that oxygen plays important roles in convoluted signalling pathways instead of being simply a nutrient.<sup>1,2</sup> Better understanding of the actions of HBO<sub>2</sub> on vascular function in diabetes mellitus and other disorders is the crucial requirement for more efficient clinical use, better prediction of outcome or unwanted/adverse results, more precise decisions about suitability and further development of therapeutic methods. It is, however, also a prerequisite for completely elucidating the roles of oxygen as a key factor in physiological processes and for further advances in experimental research.

<sup>1</sup>Faculty of Medicine, University of Osijek, Osijek, Croatia

<sup>2</sup>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA

### Corresponding author:

Ines Drenjancevic, Faculty of Medicine, University of Osijek, J. Huttlera 4, HR-31000 Osijek, Croatia.

Email: ines.drenjancevic@mefos.hr

In previous studies, which investigated the effects of HBO<sub>2</sub> on aortic ring reactivity to angiotensin-(1-7) (ANG-(1-7)) and angiotensin II (ANG II) in healthy Sprague–Dawley rats, it has been found that HBO<sub>2</sub> enhances aortic vascular reactivity to ANG-(1-7), but does not alter reactivity to ANG II.<sup>7</sup> Furthermore, it has been shown that the specific epoxidation inhibitor *n*-methylsulphonyl-6-(2-propargyloxyphenyl)hexanamide ((MS-PPOH) which inhibits specific cytochrome P450 (CYP) enzyme reactions that produce epoxyeicosatrienoic acids (EETs)) reverses the observed changes of HBO<sub>2</sub> on vascular reactivity to ANG-(1-7).<sup>7</sup> This implies that EETs may have an important role in mediating the changes of vascular reactivity to ANG-(1-7) induced by HBO<sub>2</sub>.<sup>7</sup> This is extremely interesting, since both ANG-(1-7) (which has dilative properties that counteract ANG II contraction) and EETs have beneficial effects on vasculature in diabetes, as shown in various earlier studies.<sup>8–14</sup> A number of works discovered disturbances of vascular reactivity in diabetes – notably, increased reactivity to physiological vasoconstrictors and decreased reactivity to vasodilators,<sup>15–21</sup> as well as impaired cerebral blood flow autoregulation.<sup>22</sup> In streptozocin-induced diabetic rats, vasodilation to acetylcholine is impaired, as is arteriolar flow-dependent dilation.<sup>20,23,24</sup> In such rat models of diabetes, contraction to noradrenalin in aorta, skeletal arteries and mesenteric arteries is increased.<sup>15,25,26</sup> ANG-(1-7) was demonstrated to improve the damaged vascular reactivity to various constrictors and dilators in diabetes and to facilitate recovery from ischaemia-reperfusion injury in hearts of streptozocin-induced diabetic rats.<sup>8,10</sup> The synthetic ANG-(1-7) agonist NorLeu(3)-ANG-(1-7) accelerates healing of diabetic wounds.<sup>11</sup>

The biological roles of EETs in vascular function are extremely important – they serve as an endothelium-derived hyperpolarizing factor, with their vasodilating effect being comparable to that of acetylcholine.<sup>27</sup> Besides causing vasodilation, by increasing potassium influx into smooth muscle cells, they have pro-angiogenic, anti-inflammatory, anti-apoptotic and pro-fibrinolytic effects.<sup>28–31</sup> In their role of regulating blood flow, some EETs can also exhibit vasoconstrictive properties, for example, in the kidney where they can cause constriction of the afferent arteriole.<sup>27,32</sup> They are synthesized in epoxidation reactions (as arachidonic acid metabolites) catalysed by a number of specific CYP enzymes capable of epoxidation.<sup>27,33</sup> EETs are capable of modulating vascular responses to other stimuli, such as hormonal and paracrine agents. For instance, vasopressin-induced increase in cytosol calcium in mesangial cells is enhanced by EETs and reduced with inhibition of EETs synthesis.<sup>27</sup> Responses of afferent arterioles to ANG II, endothelin-1 and noradrenalin increase with inhibition of EETs.<sup>27</sup> Importantly, EETs were shown to be protective against streptozocin-induced diabetic nephropathy<sup>12,34</sup> and coronary artery disease,<sup>13</sup> whereas inhibition of EETs synthesis worsens stroke in rats

with streptozocin-induced diabetes mellitus type 1.<sup>14</sup> Meanwhile, diabetes induced with streptozocin in rats causes a decrease in levels of protective EETs.<sup>14</sup> Some CYP enzymes were also found to act as oxygen sensors in tissues, with production of EETs and hydroxyeicosatetraenoic acids (HETEs) directly correlating with pO<sub>2</sub>.<sup>35–37</sup> This fact brings CYP enzymes (probably also those capable of EETs synthesis) into focus as possible targets of HBO<sub>2</sub>.

A facilitation of vascular reactivity to ANG-(1-7) in diabetes, similar to the facilitation reported in healthy rats, would therefore explain some of the beneficial effects of HBO<sub>2</sub> in diabetic wound healing and in other vascular pathologic conditions associated with diabetes. The aim of this work was to investigate the influence of HBO<sub>2</sub> on aortic ring reactivity to ANG-(1-7) and ANG II in diabetic rats and to test whether inhibition of EETs synthesis reverses effects of HBO<sub>2</sub>. Furthermore, the effect of HBO<sub>2</sub> on mRNA and protein expression of important rat CYP enzymes (synthesizing EETs) in aorta was assessed. The main hypothesis is that HBO<sub>2</sub> enhances aortic relaxation after ANG-(1-7) addition, without significantly altering aortic reactivity to ANG II, and that EETs play an important role in this enhancement. Under this hypothesis, inhibition of EETs synthesis would be expected to reverse any facilitation of vascular reactivity induced by HBO<sub>2</sub> and HBO<sub>2</sub> would possibly cause an upregulation of CYP enzymes that synthesize EETs.

## Methods

### *Animals and model of diabetes*

Male Sprague–Dawley rats were housed doubly in shoebox style cages with free access to standard rat chow and tap water, maintained on a 12:12-h light:dark cycle. A type 1 diabetes mellitus model was induced by injecting streptozocin (60 mg/kg) intraperitoneally at 6 weeks of age. Blood glucose levels were checked 1 week after the injection and again on the day of the experiment (at an age of 14 weeks). All animals that did not develop diabetes at 1 week after the injection (or without confirmed diabetes again at 14 weeks) were euthanized and not used in further experiments. From experience in our laboratory, we set the minimum blood glucose cut-off at the age of 7 weeks at 15 mmol/L (with ~80% of injected rats in our facility satisfying this requirement), because with such a high initial cut-off, most of the remaining rats indeed successfully develop diabetes. Therefore, only three rats (3.85%) planned for the aortic vascular reactivity assay and four rats (4.88%) planned for the other experiments had to be excluded (prior to entering experiments) at the 14-week blood glucose check for not developing diabetes. A OneTouch Ultra (LifeScan, Inc., Milpitas, CA, USA) glucometer and the tail cut method were used to measure blood glucose levels (with the vast majority of successfully developed diabetic animals at 14 weeks of age

showing a level 'higher than 33.3 mmol/L' – the measurements were used only as a confirmation of successful development of the diabetes model).

At the age of 14 weeks, rats were divided into a control group and an HBO<sub>2</sub> group which underwent the HBO<sub>2</sub> protocol. Rats from the HBO<sub>2</sub> group were treated in a hyperbaric chamber (containing CO<sub>2</sub> adsorbent) with 100% O<sub>2</sub> (using pressure of 2 bar) for 2 h a day (with addition of 15 min for the compression phase and 15 min for the decompression phase) during four consecutive days. On the fifth day, the aortic ring experiments were conducted. For that purpose, the rats were anaesthetized with a combination of ketamine (75 mg/kg) and midazolam (2.5 mg/kg) and afterwards decapitated with a guillotine. The abdomen and thorax were surgically opened and the lungs, heart, oesophagus and adjacent tissue removed. The thoracic aorta was carefully and promptly isolated, placed into an oxygenated Krebs–Henseleit solution and cleaned of adherent tissue. The procurement of animals, the husbandry and the experiments conformed to the 'European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes' (Council of Europe No 123, Strasbourg 1985). The experiments were approved by the Ethics committee of the Faculty of Medicine, University of Osijek.

### Reagents

ANG II and ANG-(1-7), noradrenaline and acetylcholine were purchased from Sigma–Aldrich. Ketamine and midazolam were obtained from Pfizer, New York, NY, USA. Streptozocin was purchased from Sigma–Aldrich. The Krebs–Henseleit solution (composition: 113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO<sub>4</sub> × 7H<sub>2</sub>O, 22 mM NaHCO<sub>3</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 11 mM glucose, 2.5 mM CaCl<sub>2</sub> × 2H<sub>2</sub>O, 0.026 mM ethylenediaminetetraacetic acid (EDTA); pH 7.4) was prepared from EDTA and purchased from Sigma–Aldrich, CaCl<sub>2</sub> × 2H<sub>2</sub>O and NaHCO<sub>3</sub> from Merck KGaA, Darmstadt, Germany, with the rest of the chemicals purchased from Kemika, Zagreb, Croatia. MS-PPOH, a selective inhibitor of the epoxidation reactions catalysed by specific CYP450 isozymes, was a gift from John R. Falck, Southwestern Medical Center, Dallas, TX, USA. MS-PPOH is a reaction-specific inhibitor and is not isoform-specific: it selectively inhibits epoxidation in various CYP isoforms that are capable of catalysing these reactions,<sup>38</sup> although it is often mentioned that it inhibits CYP4A2 and CYP4A3, which are merely some of the first isoforms on which this epoxidation inhibition was confirmed.<sup>38</sup> The CO<sub>2</sub> adsorbent Drägerorb 800 Plus was produced by Dräger, Lübeck, Germany.

### Aortic vascular reactivity assay

Short segments from each end of the isolated aorta were severed and discarded, whereas the rest of the vessel was cut into rings (of about 3–4 mm in length). These rings were

mounted in tissue bath chambers containing Krebs–Henseleit solution (maintained at 37°C) with 95% O<sub>2</sub>/5% CO<sub>2</sub> compressed gas mixture bubbling through and connected to pressure transducers as part of an Experimetria vessel ring preparation setup (purchased from Experimetria Ltd, Budapest, Hungary). The data were continuously recorded on a computer and later analysed. Passive tension for each ring was set at 2.0 g. The vessels were allowed to equilibrate and stabilize for 1 h, replacing the Krebs–Henseleit solution every 15 min with fresh solution and readjusting passive tension to 2.0 g as needed. Subsequently, intactness of endothelium was tested by precontracting the rings with 10<sup>-7</sup> M (final concentration) noradrenaline, letting stabilize for 5 min and inducing relaxation with 10<sup>-5</sup> M acetylcholine. If the vessel ring failed to relax, it was not used for further studies (in this series of experiments, one ring from the diabetic control group and one from the HBO<sub>2</sub> group were excluded, which accounts for 1.83% of the overall aortic rings). If the vessel ring relaxed, it was washed three times with fresh solution and allowed to equilibrate for 30 min, with washing at 10-min intervals. After the rings were stabilized, maximal contraction was induced with 60 mM KCl + 10<sup>-7</sup> noradrenaline. When plateau was reached, the rings were washed three times with fresh solution and allowed to equilibrate for 30 min, washing at 10-min intervals.

After this phase, aortic ring responses to ANG II or ANG-(1-7) were tested, by treating every ring of a certain animal with a different peptide/protocol and only once. The concentrations for the peptides were chosen on the basis of previous studies where such concentrations were effective.<sup>39–41</sup> In one chamber, 10<sup>-6</sup> M ANG II was applied. A second aortic ring was treated with 10<sup>-6</sup> M ANG II + 10<sup>-6</sup> M ANG-(1-7) – to test the diminishing effect of ANG-(1-7) on ANG II contraction. Another ring was precontracted with noradrenaline for 5 min, after which 10<sup>-6</sup> M ANG-(1-7) was added and the tension read after 3 min. In this way, in experiments which test a certain substance response (e.g. response to ANG II or response to ANG II + ANG-(1-7)), the number 'n' corresponds simultaneously to the number of animals and to the number of rings (because every aortic ring tested for this substance is from a different animal). The peak contraction force of the responses to ANG II and ANG II + ANG-(1-7) was expressed as percentage of maximal contraction of the particular ring, and thereby, the contractile response for a certain substance was normalized to the maximal contraction of that ring. The responses to ANG-(1-7) were expressed as percentage of precontraction decrease (after 3 min of ANG-(1-7) presence). Aortic responses to noradrenaline were also evaluated.

To explore the role of EETs in mediating the potential facilitation of vasodilatory effects of ANG-(1-7) by the HBO<sub>2</sub> protocol, the selective epoxidation inhibitor MS-PPOH was used. In a series of experiments with HBO<sub>2</sub> rats, MS-PPOH (10<sup>-5</sup> M final concentration) was added 15 min before precontraction with noradrenaline (and subsequent addition of ANG-(1-7)).

### *CYP mRNA expression studies*

Quantitative polymerase chain reaction (Q-PCR) was performed to detect the expression levels of CYP4A2 and CYP4A3 (which are some of the important isoforms inhibited by MS-PPOH), as well as CYP2J3 and CYP4A1 in HBO<sub>2</sub> and control samples of diabetic rats. Aorta samples were collected and stored in RNAlater (Qiagen, Hilden, Germany) on  $-80^{\circ}\text{C}$  until RNA isolation. Total RNA was extracted using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) according to the manufacturer's instructions. RNA concentration and purity was assessed using NanoDrop (Thermo Scientific, Waltham, MA, USA). Using a Deoxyribonuclease kit (Sigma, St Louis, MO, USA), total RNA was additionally purified from gDNA. Reverse transcription was performed with High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instruction on MyCycler Thermal Cycler (BioRad, Hercules, CA, USA). Quantitative real-time PCR was performed on an AB7500 (Applied Biosystems) platform, determining the expression of mRNA for CYP4A1, CYP4A2 and CYP4A3. For that purpose, TaqMan Gene Expression Assay products Rn04224034\_s1, Rn01417068\_g1 and Rn00598412\_m1 were used. CYP2J3 mRNA expression was determined with the use of custom-made primers designed on Primer Express (Applied Biosystems) using ABsolute Q-PCR SYBR Green low ROX master mix (Thermo Scientific) – also on the Applied Biosystems 7500 real-time PCR System. Gene expression (CYP mRNA expression) was normalized to the expression of two housekeeping genes – hypoxanthine-guanine phosphoribosyltransferase (HPRT) and 18S.

### *CYP protein expression studies*

Western blot was performed to assess CYP protein expression. Specific primary mouse monoclonal antibodies to CYP2C11 (Gentaur, Kampenhout, Belgium) were used in conjunction with secondary goat anti-mouse IgG antibodies labelled with horseradish peroxidase (HRP; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). To detect CYP2J3 expression, a specific rabbit polyclonal antibody with attached HRP (Antibodies-Online Inc., Atlanta, GA, USA) was used. Aorta samples were promptly frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  until homogenization. Homogenization was performed on ice, with appropriate buffer (1mM EDTA, 10mM Tris (Fisher Scientific, Loughborough, UK), 0.4% sodium dodecyl sulphate (SDS; Acros Organics, USA, Geel, Belgium), protease inhibitor cocktail 0.4  $\mu\text{L}/100\mu\text{L}$  (Sigma–Aldrich)) and with an ULTRA-TURRAX homogenizer (IKA, Staufen, Germany). A Bradford assay (AppliChem, Darmstadt, Germany) was used to determine total sample protein concentrations. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent blotting to

polyvinylidene difluoride (PVDF) membranes were performed at  $4^{\circ}\text{C}$  with BioRad protein electrophoresis and blotting systems (Mini-PROTEAN Tetra Cell and Criterion blotter) and an appropriate BioRad power supply system. After membrane blocking, primary and secondary antibody incubation phases (or in case of CYP2J3, incubation with one joint HRP-labelled antibody) and washing phases, detection was performed with a chemiluminescence method. For that purpose, Pierce enhanced chemiluminescence (ECL) Western Blotting Substrate (Thermo Scientific) was used according to the manufacturer's instructions and the signal was recorded on X-ray films in a dark chamber. Expression of CYP2J3 and CYP2C11 for each sample was normalized to  $\beta$ -actin expression (primary  $\beta$ -actin mouse monoclonal antibodies were purchased from Sigma–Aldrich). ImageJ software was used to process and analyse the CYP2J3 and CYP2C11 protein expression (relative to  $\beta$ -actin expression) in concordance with the software developer's instructions.

### *Arterial blood pressure and indicators of oxidative stress*

We analysed potential changes in arterial blood pressure and indicators of oxidative stress in animals with regard to treatment with the used HBO<sub>2</sub> protocol, to test whether such changes could explain HBO<sub>2</sub> effects on vascular reactivity. Because it is known from earlier work that both arterial blood pressure changes and oxidative stress can affect vascular reactivity,<sup>42–47</sup> it is important to observe the roles of these factors in analysing the effects of HBO<sub>2</sub>.

A separate batch of diabetic male Sprague–Dawley rats was divided into HBO<sub>2</sub> and control animals. After the HBO<sub>2</sub> group was subjected to the HBO<sub>2</sub> protocol, all rats have been anaesthetized with a combination of ketamine (75 mg/kg) and midazolam (2.5 mg/kg) and a catheter made of PE-50 tubing has been surgically inserted into the left femoral artery. Body temperature was maintained constant, and the mean arterial blood pressure was measured with a Spacelabs Medical monitoring system (Spacelabs Medical, Inc., Redmond, WA, USA). After 10 min of stabilization, the blood pressure was determined as the average blood pressure during a period of 1 min.

As indicators of oxidative stress, ferric reducing ability of plasma (FRAP)<sup>48</sup> and Thiobarbituric Acid Reactive Substances (TBARS)<sup>49</sup> have been determined from blood samples in separate batches of anaesthetized HBO<sub>2</sub> and control diabetic animals. The FRAP assay offers an index of antioxidant, or reducing, potential and uses Trolox as a standard, whereas the TBARS assay is used to detect by-products of lipid peroxidation (malondialdehyde (MDA) is used as standard).

### ANG-(1-7) serum levels

Additionally, ANG-(1-7) serum levels were determined, since HBO<sub>2</sub> was found to facilitate vascular relaxation to ANG-(1-7). This was done to assess whether a potential change in ANG-(1-7) concentration induced by HBO<sub>2</sub> could be responsible for the mechanism of vascular reactivity changes to ANG-(1-7) – it is widely known that agonists can induce internalization and desensitization of its receptors, depending on the change of agonist quantity, leading to alterations in agonist efficacy (and signal transduction).<sup>50,51</sup> For that purpose, enzyme-linked immunosorbent assay (ELISA) was used to measure ANG-(1-7) concentrations in serum samples of control diabetic rats and diabetic rats that underwent the HBO<sub>2</sub> protocol. The rat ANG-(1-7) ELISA kit was purchased from USCN Life Sciences Inc. (Wuhan, China) and used by following the manufacturer's instructions.

### Statistical analysis

Statistics were performed using SigmaPlot 11.2 (Systat Software, Inc., San Jose, CA, USA). Contraction to ANG II (mean percentage of maximal contraction) was compared between the HBO<sub>2</sub> and the control group. Similarly, in experiments measuring contraction to ANG II+ANG-(1-7), the mean percentage of maximal contraction was compared between the two groups and, likewise, experiments determining the mean percentage of precontraction decrease after ANG-(1-7) addition were analysed as well. Within the control and within the HBO<sub>2</sub> group, the difference between contraction to ANG II and ANG II+ANG-(1-7) was tested (since every peptide was applied to a distinct aortic ring). Shapiro–Wilk test was used as normality test. If it was passed, Student's t-test was used with significance set at  $p < 0.05$ . If the normality test was not passed, the non-parametric Mann–Whitney U test was used with significance set at  $p < 0.05$ . Results from the HBO<sub>2</sub> group where MS-PPOH was added before application of the peptides were compared with HBO<sub>2</sub> animals where no MS-PPOH was applied in a similar manner. Results are expressed as mean  $\pm$  standard deviation (SD).

Statistical analysis of CYP expression levels, arterial blood pressure values, indicators of oxidative stress (FRAP and TBARS) and ANG-(1-7) serum levels, compared between the HBO<sub>2</sub> and control groups, was performed with the use of Student's t-test or Mann–Whitney U test, respective of the outcome of the Shapiro–Wilk normality test, with significance set at  $p < 0.05$ .

## Results

### Aortic vascular reactivity experiments

Contractile responses to ANG II were similar in both control diabetic rats and diabetic rats treated with HBO<sub>2</sub> (Figure 1(a)). The mean percentage of maximal contraction

for ANG II responses was  $14.8\% \pm 7.1$  (N=11) in the control group and  $16.4\% \pm 5.9$  (N=12) in the HBO<sub>2</sub> group ( $p > 0.05$ , Student's t-test). Contractile aortic ring responses to the combination of ANG II+ANG-(1-7), as shown in Figure 1(a), were similar between control (N=19) and HBO<sub>2</sub> (N=19) rats ( $p > 0.05$ , Student's t-test).

Relaxation to ANG-(1-7) (mean percentage of noradrenaline precontraction decrease 3 min after ANG-(1-7) addition) was  $12.1\% \pm 6.4$  (N=14) in diabetic control rats compared to  $19.2\% \pm 7.3$  (N=18) in diabetic HBO<sub>2</sub> rats. This difference was statistically significant ( $p = 0.007$ , Student's t-test) (Figure 1(a)). HBO<sub>2</sub> had no effect on the responses to noradrenaline alone, since the contraction to noradrenaline (expressed as mean percentage of maximal contraction) was similar in both control and HBO<sub>2</sub> animals (Figure 1(b)).


When the selective epoxidation inhibitor MS-PPOH was added before precontraction with noradrenaline and ANG-(1-7) addition to aortic rings of HBO<sub>2</sub> diabetic rats, mean relaxation to ANG-(1-7) was  $5.7\% \pm 5.1$  (N [DM+HBO<sub>2</sub>]=18, N [DM+HBO<sub>2</sub>/MS-PPOH]=16). This was a statistically significantly lower relaxation response compared to responses of HBO<sub>2</sub> rings when no MS-PPOH was used ( $p < 0.001$ , Student's t-test) (Figure 2). Figure 5 shows contraction to noradrenaline alone of HBO<sub>2</sub> rings treated with MS-PPOH compared to untreated HBO<sub>2</sub> rings. There was no significant effect of MS-PPOH on contraction responses to noradrenaline ( $p > 0.05$ , Student's t-test).

### CYP mRNA expression studies

Figure 3 shows relative aortic mRNA expression levels (determined with Q-PCR) for CYP2J3, CYP4A1, CYP4A2 and CYP4A3. The CYP2J3 aortic mRNA expression (N [DM]=9, N [DM+HBO<sub>2</sub>]=9) is statistically significantly higher in the HBO<sub>2</sub> group of diabetic animals compared to diabetic animals which did not undergo HBO<sub>2</sub> protocol exposure ( $p < 0.05$ , Mann–Whitney U test). This is evident when analysed with either of the two measured housekeeping genes (HPRT and 18S). Relative aortic mRNA expression of CYP4A1 (N [DM]=9, N [DM+HBO<sub>2</sub>]=9), CYP4A2 (N [DM]=8, N [DM+HBO<sub>2</sub>]=9) and CYP4A3 (N [DM]=9, N [DM+HBO<sub>2</sub>]=9) is not significantly different between groups (with both housekeeping genes used for analysis) ( $p > 0.05$ , Mann–Whitney U test).

### CYP protein expression studies

Aortic protein expression (as assessed with Western blot) of CYP2J3 and CYP2C11 is shown in Figure 4. The relative CYP2J3 protein expression (N [DM]=11, N [DM+HBO<sub>2</sub>]=9) was not determined to be statistically significantly different in HBO<sub>2</sub> diabetic animals compared to diabetic animals which were not treated with HBO<sub>2</sub> (although HBO<sub>2</sub> expression is non-significantly higher) ( $p > 0.05$ , Student's t-test). A statistically significant



**Figure 1.** (a) Aortic vascular responses to ANG II, to the combination ANGII+ ANG-(1-7) (top) and to ANG-(1-7) (bottom). Contraction responses are expressed as mean percentage of maximal contraction after peptide addition to isolated thoracic aortic rings of diabetic control rats (DM) or diabetic rats treated with HBO<sub>2</sub> (DM + HBO<sub>2</sub>) (top). Relaxation of isolated thoracic aortic rings is expressed as mean percentage of precontraction decrease 3 min after addition of ANG-(1-7) to rings precontracted with NA (bottom). The asterisks (\*\*\*) mark statistically significant difference. (b) Aortic contraction responses to noradrenaline alone. Contraction responses are expressed as mean percentage of maximal contraction after noradrenaline addition to isolated thoracic aortic rings of diabetic control rats (DM) or diabetic rats treated with HBO<sub>2</sub> (DM + HBO<sub>2</sub>). ANG: angiotensin; HBO<sub>2</sub>: hyperbaric oxygenation; NA: noradrenaline.

upregulation of CYP2C11 aortic protein expression (N [DM]=7, N [DM+HBO<sub>2</sub>]=7) was measured in HBO<sub>2</sub> diabetic rats compared to untreated diabetic rats ( $p=0.042$ , Student's t-test).

#### Arterial blood pressure and indicators of oxidative stress


Results of measurements of arterial blood pressure and serum FRAP and TBARS levels of diabetic rats (N=6) and diabetic rats treated with HBO<sub>2</sub> (N=6) are listed in Table 1. The results are expressed as mean±SD. There was no significant effect of HBO<sub>2</sub> or diabetes on either arterial pressure, or indicators of antioxidant capacity (FRAP) or lipid peroxidation (TBARS); the values between groups are similar ( $p>0.05$ , Student's t-test or Mann-Whitney U test).

#### Serum ANG-(1-7) concentration measurements

Figure 5 shows mean serum concentrations of ANG-(1-7), as determined with ELISA, in diabetic rats (N=8) and diabetic rats treated with HBO<sub>2</sub> (N=8). The serum levels are similar in both groups, with no apparent effect of HBO<sub>2</sub> ( $p>0.05$ , Mann-Whitney U test).

#### Discussion

The obtained data from the aortic vascular reactivity experiments suggest that HBO<sub>2</sub> significantly facilitates relaxation in response to ANG-(1-7), while not affecting ANG II contraction in the animal model of diabetes. This is the first time to demonstrate these findings in diabetic rats and the findings are in concordance with previously reported effects of HBO<sub>2</sub> on vascular reactivity of healthy



**Figure 2.** Effect of MS-PPOH on vascular responses of HBO<sub>2</sub> aortic rings to ANG-(1-7) (top) or to noradrenaline alone (bottom). (Top) Relaxation of isolated thoracic aortic rings after addition of ANG-(1-7) to rings precontracted with NA. (Bottom) Contraction responses of isolated thoracic aortic rings after NA addition. Effect of the selective epoxidation inhibitor MS-PPOH on responses of HBO<sub>2</sub> rings (DM + HBO<sub>2</sub> and MS-PPOH) compared to responses of HBO<sub>2</sub> rings when no inhibitor was used (DM + HBO<sub>2</sub>). The asterisks (\*\*\*) mark statistically significant difference. MS-PPOH: *n*-methylsulphonyl-6-(2-propargyloxyphenyl)hexanamide; ANG: angiotensin; HBO<sub>2</sub>: hyperbaric oxygenation; NA: noradrenaline.


rats to ANG-(1-7).<sup>7</sup> A similar precontraction response to noradrenaline in both HBO<sub>2</sub> and control diabetic rats, as displayed in Figure 1(b), suggests that there was no non-specific effect of HBO<sub>2</sub> on precontraction, which could have falsely affected results of the ANG-(1-7) responses, and this affirms the technical accuracy of the experiments. The order of magnitude of the measured ANG-(1-7) relaxations of aortic rings corresponds roughly to extents of relaxations to ANG-(1-7) in other aortic ring experiments, for similar concentrations of ANG-(1-7).<sup>52,53</sup>

Previous studies found that ANG-(1-7) improves damaged vascular function and myocardial damage in diabetes, in addition to having other positive vascular effects in diabetes.<sup>8–10,54,55</sup> An exogenously applied agonist of ANG-(1-7) was even connected with accelerated healing of chronic diabetic wounds.<sup>11</sup> In light of these discoveries, the observed facilitation of vascular ANG-(1-7) actions by HBO<sub>2</sub> seems especially important. It may partly explain

how HBO<sub>2</sub> exerts its positive therapeutic effects in conditions with vascular pathology in diabetes.

In our aim to investigate potential mechanisms of the modulation of ANG-(1-7) vascular responses induced by HBO<sub>2</sub>, we evaluated a possible role of EETs. These arachidonic acid metabolites (with predominantly vasodilatory function) were previously found to modulate vascular reactivity to various stimuli,<sup>27,32,33</sup> to have cardioprotective and antihypertensive properties,<sup>56</sup> and to exert protective effects in stroke.<sup>14</sup> Notably, EETs show positive effects in disorders with vascular pathology in diabetes, including myocardial ischaemia-reperfusion injury, stroke, atherosclerosis, diabetic nephropathy<sup>9,12–14,34</sup> and others. The animal model of type 1 diabetes mellitus induced by streptozocin, as used in this work, leads to a reduction of protective EETs concentrations (through increase of EETs degradation).<sup>14</sup> Changes in expression of certain CYP enzymes that catalyse EETs formation are connected with beneficial effects. For example, overexpression of the CYP2J group of enzymes in mice alleviates streptozocin-induced diabetic nephropathy<sup>34</sup> and in apoE knockout mice (an atherosclerosis model) increases EETs production and protects against ANG II-induced abdominal aortic aneurysm.<sup>57</sup> Upregulation of CYP2J3 inhibits apoptosis in neonatal rat cardiomyocytes after heart ischaemia, while MS-PPOH reduces this cardioprotective effect.<sup>58</sup> In salt-sensitive stroke-prone spontaneously hypertensive rats, salt loading down-regulated CYP2C11 expression, whereas upregulation of cerebral CYP2C11 expression using clofibrate was protective against stroke and led to increase in blood vessel diameters and cerebral blood flow.<sup>59</sup> Experiments in our work demonstrated that the highly selective epoxidation inhibitor MS-PPOH reversed the facilitated aortic relaxation to ANG-(1-7) in HBO<sub>2</sub> diabetic rats. The inhibitor is highly selective and is reaction specific for epoxidation and not isoform specific,<sup>38</sup> which means that it inhibits EETs formation in a wide range of CYP isoforms that are capable of catalysing epoxidation reactions. The results, therefore, strongly indicate that EETs play an important role in the mechanism of HBO<sub>2</sub>-induced modulation of vascular responses to ANG-(1-7). Separate analysis of the effect of MS-PPOH on contraction to noradrenaline alone (as displayed in Figure 2) shows that there is no non-specific alteration of the precontraction to noradrenaline by MS-PPOH, indicating technical accuracy. A crucial role of EETs in the mechanism of beneficial vascular effects of HBO<sub>2</sub> would fit well into the framework of knowledge about EETs generated in previous research. Since they can modulate vascular reactivity in diabetes<sup>27,32,33</sup> and exert protective effects in conditions with vascular pathology in diabetes,<sup>9,12–14,34</sup> a facilitation of EETs synthesis induced by HBO<sub>2</sub> could further explain its beneficial clinical effects as well as the facilitation of vascular reactivity to ANG-(1-7). Furthermore, it has been revealed that EETs synthesis (as well as synthesis of 20-HETE) becomes decreased with a decrease in tissue pO<sub>2</sub>,<sup>35,36</sup> identifying specific CYP enzymes as biological vascular oxygen sensors with their activity depending on oxygen tension.<sup>35–37</sup>






**Figure 3.** Relative aortic mRNA expression. Relative aortic mRNA expression levels of CYP2J3 (top left), CYP4A1 (top right), CYP4A2 (bottom left) and CYP4A3 (bottom right). The expression is normalized to expression of housekeeping genes (HPRT or 18S). The asterisk (\*) and the hash (#) mark statistically significant difference between the diabetic control group (DM) and the diabetic HBO<sub>2</sub> group (DM+HBO<sub>2</sub>).

HPRT: hypoxanthine-guanine phosphoribosyl transferase; HBO<sub>2</sub>: hyperbaric oxygenation.


An intense increase in tissue pO<sub>2</sub>, as induced by HBO<sub>2</sub>, would therefore theoretically increase EETs formation and stimulate the CYP oxygen sensors.

To further elucidate the role of specific CYP epoxygenases as potential targets or effectors of HBO<sub>2</sub>, we tested the influence of HBO<sub>2</sub> on aortic expression of the important rat CYP isoforms CYP2J3, CYP4A1, CYP4A2, CYP4A3 and CYP2C11. A significant upregulation of aortic CYP2J3 mRNA and CYP2C11 protein expression was detected in HBO<sub>2</sub> diabetic rats compared to untreated diabetic rats. Such an upregulation is interesting and might partially explain the mechanisms of HBO<sub>2</sub>, but a causal relation between this upregulation and facilitation of ANG-(1-7) vascular reactivity or clinical beneficial effects cannot be determined for certain at this point. Other important

epoxygenase isoforms, such as CYP4A2 and CYP4A3, were not found to be upregulated (mRNA), and an upregulation of CYP2J3 at the mRNA level could not be verified by Western blot at the protein level (the higher protein expression in the HBO<sub>2</sub> diabetic group was not significant). It is also possible that HBO<sub>2</sub> increases vascular sensitivity to EETs, instead of significantly increasing EETs synthesis. Namely, if MS-PPOH diminishes the effects of HBO<sub>2</sub> (on ANG-(1-7)-induced relaxation) by inhibiting EETs synthesis, and EETs synthesis was not significantly increased by HBO<sub>2</sub>, then this suggests that HBO<sub>2</sub> increases the vascular sensitivity to EETs. Finally, both pathways are possible in the HBO<sub>2</sub> mechanism, based on our data, and further studies of this problem are necessary. A definitive verdict might come with future research on resistance vessels (such as the



**Figure 4.** Relative aortic protein expression of CYP2J3 (top) and CYP2C11 (bottom). The expression is normalized to expression of  $\beta$ -actin in aorta of diabetic control rats (DM) and diabetic rats that underwent HBO<sub>2</sub> (DM+HBO<sub>2</sub>). The asterisk (\*) marks statistically significant difference. HBO<sub>2</sub>: hyperbaric oxygenation.



**Figure 5.** Serum levels of ANG-(1-7). Results of ELISA measurements of serum ANG-(1-7) concentrations are compared between diabetic control rats (DM) and diabetic rats treated with HBO<sub>2</sub> (DM+HBO<sub>2</sub>). ELISA: enzyme-linked immunosorbent assay; ANG: angiotensin; HBO<sub>2</sub>: hyperbaric oxygenation.


gracilis or mesenteric arteries) and in microcirculation, where the effects of HBO<sub>2</sub> may be much more pronounced than in the aorta. The extremely low EET concentrations are difficult to measure and future high-performance liquid chromatography (HPLC) studies might investigate direct changes of EET levels induced by HBO<sub>2</sub>. Other possible pathways in the HBO<sub>2</sub> mechanism additionally complicate this framework, including partially known influences of HBO<sub>2</sub> on endothelial nitric oxide synthase (eNOS), other signalling cascades and inflammation<sup>1</sup> or conducted vasomotor responses.<sup>60,61</sup> Considering the interaction of arachidonic acid pathways with nitric oxide pathways in oxygen sensitivity<sup>36</sup> and regional differences of arachidonic acid metabolite roles,<sup>36</sup> it is evident that the role of CYP enzymes in oxygen homeostasis is very complex. Figure 6 summarizes the discussed findings and mechanisms.

The results of this work do not demonstrate any significant changes in arterial blood pressure levels or indicators of

**Table 1.** Measurements of mean arterial pressure, FRAP and TBARS.

Experimental group	Age (weeks)	Body mass (g)	Mean arterial pressure (mmHg)	FRAP (mM Trolox)	TBARS ( $\mu\text{mol MDA}$ )
DM	14 $\pm$ 0	240.0 $\pm$ 36.4	102.3 $\pm$ 5.0	0.176 $\pm$ 0.033	0.179 $\pm$ 0.049
DM+HBO <sub>2</sub>	14.0 $\pm$ 0.81	259.3 $\pm$ 23.3	105.9 $\pm$ 4.7	0.181 $\pm$ 0.028	0.261 $\pm$ 0.135

FRAP: ferric reducing ability of plasma; TBARS: Thiobarbituric Acid Reactive Substances; HBO<sub>2</sub>: hyperbaric oxygenation; MDA: malondialdehyde. The table lists results for untreated diabetic rats (DM) and diabetic animals treated with HBO<sub>2</sub> (DM+HBO<sub>2</sub>). There was no statistically significant difference between groups of either mean arterial pressure, FRAP or TBARS.



**Figure 6.** Schematic depiction of analysed HBO<sub>2</sub> effects and the discussed potential mechanisms. The observed facilitation of the dilatory effects of ANG-(1-7) by HBO<sub>2</sub> may partly be a consequence of epoxygenase upregulation (confirmed for CYP2J3, CYP2C11) or possibly a result of an increase of vascular sensitivity to EETs. Also, other possible factors (not involving EETs or other arachidonic acid metabolites) cannot be excluded as part of the mechanism.

ANG: angiotensin; HBO<sub>2</sub>: hyperbaric oxygenation; RAS: renin-angiotensin system; EET: epoxyeicosatrienoic acid.

oxidative stress induced by the HBO<sub>2</sub> protocol in diabetic rats. It was important to test this possibility, since both arterial pressure and oxidative stress affect vascular reactivity<sup>42-47</sup> and there are also interconnections between ANG-(1-7) and oxidative stress.<sup>62</sup> Data from previous publications on HBO<sub>2</sub> influence on arterial pressure are not univocal: HBO<sub>2</sub> can by various accounts and under different conditions increase,<sup>63-65</sup> decrease<sup>66</sup> or leave blood pressure unchanged.<sup>65,67,68</sup> However, the data cannot be readily compared because of vast differences in HBO<sub>2</sub> protocols (acute or chronic exposure, differences in exposure duration and pressure levels), underlying conditions of the treated groups (diabetic, spontaneously hypertensive, healthy) or experimental models (humans, animals). It is necessary to

establish standardized reference values for specific conditions and protocols. We therefore measured mean arterial pressure for this specific protocol used in diabetic rats and found it to be unchanged in the HBO<sub>2</sub> group. The lack of changes of FRAP and TBARS levels in our results is not surprising, since with the use of this protocol of intermittent HBO<sub>2</sub>, the experiments are performed on the fifth day of the protocol – 24h after the last HBO<sub>2</sub> exposure. The results are consistent with previously published investigations<sup>69</sup> of a single HBO<sub>2</sub> exposure (in healthy rats) of the same duration and pressure level as used in this study, where elevated TBARS levels (and decreased FRAP) returned to normal within 24h after the single HBO<sub>2</sub> exposure. There is also the question of adaptation – a possible induction of antioxidant

systems<sup>1,7,69</sup> after repetitive HBO<sub>2</sub> exposures might be responsible for normalization of oxidative stress indicators. Either way, our results suggest that changes in mean arterial pressure or oxidative stress levels do not constitute part of the mechanism of observed HBO<sub>2</sub> effects on vascular reactivity to ANG-(1-7), although there is no way to exclude a hidden signalling effect<sup>1</sup> of intermittent oxidative stress elevations or antioxidant system induction.

Earlier studies showed that HBO<sub>2</sub> could influence levels of certain components of the renin–angiotensin system, such as renin levels.<sup>70–72</sup> The effect of HBO<sub>2</sub> on ANG-(1-7) serum concentrations was not investigated until now. This is of particular importance here because HBO<sub>2</sub> was found to modulate vascular responses to ANG-(1-7) and it is known that changes in agonist levels can, in general, change agonist efficacy and signal transduction – because of internalization and desensitization of its receptors.<sup>50,51</sup> The data show that there was no change of serum ANG-(1-7) levels in diabetic rats treated with HBO<sub>2</sub>, excluding the possibility that such a change would form part of the mechanism of HBO<sub>2</sub> influence on vascular reactivity to ANG-(1-7). This corroborates the discussed role of EETs and CYP enzymes as the primary focus of HBO<sub>2</sub> vascular mechanisms. These results may also have broader significance, because it is useful to know that HBO<sub>2</sub> does not seem to decrease the beneficial ANG-(1-7) in the serum of diabetic subjects.

A more complete knowledge about the exact mechanisms that mediate HBO<sub>2</sub> effects in vasculature is an essential prerequisite for efficient clinical use and optimization of HBO<sub>2</sub> as a therapeutic and investigative tool. HBO<sub>2</sub> is being used for treatment and experiments for many years, without fully comprehending the changes it induces in the circulation and at the molecular and cellular level. This study represents a further step in elucidating the underlying mechanisms of HBO<sub>2</sub> influence and is a foundation for additional investigations (that should also include human subjects). Understanding the actions of HBO<sub>2</sub> is not only important if we want to advance protocols, evaluate indications and contraindications and improve therapeutic results, but is also the basis for predicting adverse and unwanted effects and interactions with medications. This is especially so in a time of an immense global burden of diabetes<sup>73</sup> and linked cardiovascular disease,<sup>74</sup> and a wide use of multiple medications such as ones that act on the renin–angiotensin system.

## Conclusion

HBO<sub>2</sub> significantly increases vascular responses to ANG-(1-7) in diabetic rats, what could potentially explain some of the observed positive effects of HBO<sub>2</sub> in pathologic conditions (such as chronic diabetic ulcers). EETs seem to play an important role in the mechanism of this modulation. HBO<sub>2</sub> increases the expression of specific CYP isoforms, but it is also possible that it increases the vascular sensitivity to EETs. The changes in vascular reactivity

were not a consequence of a possible change in arterial blood pressure, oxidative stress or ANG-(1-7) blood levels. HBO<sub>2</sub> does not significantly alter reactivity to ANG II in diabetic rats. Better knowledge of mechanisms of HBO<sub>2</sub> effects in the vasculature of diabetic subjects is necessary for more efficient clinical use and represents a foundation for future research.

## Acknowledgements

The authors wish to thank Dr Ana Cavka for her help with aortic ring statistical analysis.

## Declaration of conflicting interests

The authors declare that there is no conflict of interest.

## Funding

This work has been funded by a grant of the Croatian Ministry of Science, Education and Sports 219-2160133-2034.

## References

- Drenjancevic I and Kibel A. Restoring vascular function with hyperbaric oxygen treatment: recovery mechanisms. *J Vasc Res* 2014; 51: 1–13.
- Tandara AA and Mustoe TA. Oxygen in wound healing – more than a nutrient. *World J Surg* 2004; 28: 294–300.
- Kudchodkar BJ, Wilson J, Lacko A, et al. Hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol* 2000; 20: 1637–1643.
- Kudchodkar BJ, Pierce A and Dory L. Chronic hyperbaric oxygen treatment elicits an anti-oxidant response and attenuates atherosclerosis in apoE knockout mice. *Atherosclerosis* 2007; 193: 28–35.
- Camporesi EM. *Hyperbaric oxygen therapy: committee report*. Kensington, MD: Undersea and Hyperbaric Medical Society, 1996, 74 pp.
- Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. *Diabetes Metab Res Rev* 2000; 16(Suppl. 1): S55–S58.
- Kibel A, Cavka A, Cosic A, et al. Effects of hyperbaric oxygenation on vascular reactivity to angiotensin II and angiotensin-(1-7) in rats. *Undersea Hyperb Med* 2012; 39: 1053–1066.
- Yousif MH, Dhaunsi GS, Makki BM, et al. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. *Pharmacol Res* 2012; 66: 269–275.
- Yousif MH, Benter IF and Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. *Auton Autacoid Pharmacol* 2009; 29: 33–41.
- Benter IF, Yousif MH, Cojocel C, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. *Am J Physiol Heart Circ Physiol* 2007; 292: H666–H672.
- Rodgers K, Verco S, Bolton L, et al. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). *Expert Opin Investig Drugs* 2011; 20: 1575–1581.

12. Chen G, Xu R, Wang Y, et al. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy. *Am J Physiol Endocrinol Metab* 2012; 303: E563–E575.
13. Theken KN, Schuck RN, Edin ML, et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. *Atherosclerosis* 2012; 222: 530–536.
14. Jouihan SA, Zuloaga KL, Zhang W, et al. Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus. *J Cereb Blood Flow Metab* 2013; 33: 1650–1656.
15. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. *Hypertension* 1998; 31: 1047–1060.
16. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? *Am J Physiol Heart Circ Physiol* 2001; 281: H981–H986.
17. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 2001; 88: E14–E22.
18. Zenere BM, Arcaro G, Saggiani F, et al. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. *Diabetes Care* 1995; 18: 975–982.
19. Gazis A, White DJ, Page SR, et al. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. *Diabet Med* 1999; 16: 304–311.
20. Bagi Z and Koller A. Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. *J Vasc Res* 2003; 40: 47–57.
21. Benter IF, Yousif MH, Canatan H, et al. Inhibition of Ca<sup>2+</sup>/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. *Pharmacol Res* 2005; 52: 252–257.
22. Bentsen N, Larsen B and Lassen NA. Chronically impaired autoregulation of cerebral blood flow in long-term diabetics. *Stroke* 1975; 6: 497–502.
23. Lash JM and Bohlen HG. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. *Circ Res* 1991; 69: 1259–1268.
24. Sartoretto JL, Melo GA, Carvalho MH, et al. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression. *Life Sci* 2005; 77: 2676–2689.
25. Ungvari Z, Pacher P, Kecskemeti V, et al. Increased myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of increased activity of smooth muscle Ca<sup>2+</sup> channels and protein kinase C. *Cardiovasc Res* 1999; 43: 1018–1028.
26. Savage MW, Bodmer CW, Walker AB, et al. Vascular reactivity to noradrenaline and neuropeptide Y in the streptozotocin-induced diabetic rat. *Eur J Clin Invest* 1995; 25: 974–979.
27. Zhao X and Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. *Curr Drug Metab* 2003; 4: 73–84.
28. Alkayed NJ, Birks EK, Hudetz AG, et al. Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. *Am J Physiol* 1996; 271: H1541–H1546.
29. Liclican EL, Doumad AB, Wang J, et al. Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. *Hypertension* 2009; 54: 1284–1290.
30. Pozzi A, Macias-Perez I, Abair T, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. *J Biol Chem* 2005; 280: 27138–27146.
31. Xu X, Zhang XA and Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. *Adv Drug Deliv Rev* 2011; 63: 597–609.
32. Wang MH, Brand-Schieber E, Zand BA, et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. *J Pharmacol Exp Ther* 1998; 284: 966–973.
33. Lianos EA. *Eicosanoid protocols*, vol. 120 (Methods in molecular biology). Totowa, NJ: Springer (Humana Press), 1999.
34. Chen G, Wang P, Zhao G, et al. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. *Prostaglandins Other Lipid Mediat* 2011; 96: 63–71.
35. Harder DR, Narayanan J, Birks EK, et al. Identification of a putative microvascular oxygen sensor. *Circ Res* 1996; 79: 54–61.
36. Kerkhof CJ, Bakker EN and Sipkema P. Role of cytochrome P-450 4A in oxygen sensing and NO production in rat cremaster resistance arteries. *Am J Physiol* 1999; 277: H1546–H1552.
37. Baragatti B, Ciofini E, Scelba F, et al. Cytochrome P-450 3A13 and endothelin jointly mediate ductus arteriosus constriction to oxygen in mice. *Am J Physiol Heart Circ Physiol* 2011; 300: H892–H901.
38. Brand-Schieber E, Falck JF and Schwartzman M. Selective inhibition of arachidonic acid epoxidation in vivo. *J Physiol Pharmacol* 2000; 51: 655–672.
39. Grobe JL and Katovich MJ. Alterations in aortic vascular reactivity to angiotensin 1-7 in 17-beta-estradiol-treated female SD rats. *Regul Pept* 2006; 133: 62–67.
40. Zhi JM, Chen RF, Wang J, et al. Comparative studies of vasodilating effects of angiotensin-(1-7) on the different vessels. *Sheng li xue bao [Acta Physiol Sin]* 2004; 56: 730–734.
41. Do KH, Kim MS, Kim JH, et al. Angiotensin II-induced aortic ring constriction is mediated by phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway. *Exp Mol Med* 2009; 41: 569–576.
42. Boegehold MA. Microvascular structure and function in salt-sensitive hypertension. *Microcirculation* 2002; 9: 225–241.
43. Falcone JC, Granger HJ and Meininger GA. Enhanced myogenic activation in skeletal muscle arterioles from spontaneously hypertensive rats. *Am J Physiol* 1993; 265: H1847–H1855.
44. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. *N Engl J Med* 2002; 346: 1954–1962.

45. Mayhan WG, Faraci FM and Heistad DD. Impairment of endothelium-dependent responses of cerebral arterioles in chronic hypertension. *Am J Physiol* 1987; 253: H1435–H1440.
46. Swee A, Lacy F, DeLano FA, et al. Oxidative stress in the Dahl hypertensive rat. *Hypertension* 1997; 30: 1628–1633.
47. Zicha J, Dobesova Z and Kunes J. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: the possible role of superoxide anions. *J Hypertens* 2001; 19: 247–254.
48. Benzie IF and Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. *Anal Biochem* 1996; 239: 70–76.
49. Oakes KD and Van Der Kraak GJ. Utility of the TBARS assay in detecting oxidative stress in white sucker (*Catostomus commersoni*) populations exposed to pulp mill effluent. *Aquat Toxicol* 2003; 63: 447–463.
50. Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. *Br J Pharmacol* 2009; 158: 165–168.
51. Oliveira L, Costa-Neto CM, Nakaie CR, et al. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure. *Physiol Rev* 2007; 87: 565–592.
52. Silva DM, Gomes-Filho A, Olivon VC, et al. Swimming training improves the vasodilator effect of angiotensin-(1-7) in the aorta of spontaneously hypertensive rat. *J Appl Physiol (1985)* 2011; 111: 1272–1277.
53. Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. *J Pharmacol Exp Ther* 2009; 328: 849–854.
54. Kilarikaje N, Yousif MH, El-Hashim AZ, et al. Role of angiotensin II and angiotensin-(1-7) in diabetes-induced oxidative DNA damage in the corpus cavernosum. *Fertil Steril* 2013; 100: 226–233.
55. Giani JF, Burghi V, Veiras LC, et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. *Am J Physiol Renal Physiol* 2012; 302: F1606–F1615.
56. Neckar J, Kopkan L, Huskova Z, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits anti-hypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. *Clin Sci* 2012; 122: 513–525.
57. Cai Z, Zhao G, Yan J, et al. CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice. *J Lipid Res* 2013; 54: 1448–1456.
58. Wang HX, Zhang DM, Zeng XJ, et al. Upregulation of cytochrome P450 2J3/11,12-epoxyeicosatrienoic acid inhibits apoptosis in neonatal rat cardiomyocytes by a caspase-dependent pathway. *Cytokine* 2012; 60: 360–368.
59. Ying CJ, Noguchi T, Aso H, et al. The role of cytochrome p-450 in salt-sensitive stroke in stroke-prone spontaneously hypertensive rats. *Hypertens Res* 2008; 31: 1821–1827.
60. Drenjancevic-Peric I, Gros M and Kibel A. Influence of hyperbaric oxygen on blood vessel reactivity: concept of changes in conducted vasomotor response. *Coll Antropol* 2009; 33: 681–685.
61. Ngo AT, Jensen LJ, Riemann M, et al. Oxygen sensing and conducted vasomotor responses in mouse cremaster arterioles in situ. *Pflugers Arch* 2010; 460: 41–53.
62. Moon JY, Tanimoto M, Gohda T, et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. *Am J Physiol Renal Physiol* 2011; 300: F1271–F1282.
63. Al-Waili NS, Butler GJ, Beale J, et al. Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension. *Arch Med Res* 2006; 37: 991–997.
64. Bergo GW and Tyssebotn I. Cerebral blood flow distribution during exposure to 5 bar oxygen in awake rats. *Undersea Biomed Res* 1992; 19: 339–354.
65. Demchenko IT, Luchakov YI, Moskvina AN, et al. Cerebral blood flow and brain oxygenation in rats breathing oxygen under pressure. *J Cereb Blood Flow Metab* 2005; 25: 1288–1300.
66. Nagatomo F, Fujino H, Takeda I, et al. Effects of hyperbaric oxygenation on blood pressure levels of spontaneously hypertensive rats. *Clin Exp Hypertens* 2010; 32: 193–197.
67. Bergo GW, Risberg J and Tyssebotn I. Effect of 5 bar oxygen on cardiac output and organ blood flow in conscious rats. *Undersea Biomed Res* 1988; 15: 457–470.
68. Nakada T, Koike H, Katayama T, et al. Increased adrenal epinephrine and norepinephrine in spontaneously hypertensive rats treated with hyperbaric oxygen. *Hinyokika kyo/Acta urologica Japonica* 1984; 30: 1357–1366.
69. Drenjancevic I, Kibel A, Kibel D, et al. Blood pressure, acid-base and blood gas status and indicators of oxidative stress in healthy male rats exposed to acute hyperbaric oxygenation. *Undersea Hyperb Med* 2013; 40: 319–328.
70. Khaidarova G, Borukhova ES and Asinova MI. Effect of hyperbaric oxygenation on the status of the renin-angiotensin-aldosterone system in chronic circulatory insufficiency in elderly patients with ischemic heart disease. *Anesteziol Reanimatol* 1989; 3: 33–35.
71. Pakharukova NA, Pastushkova L, Popova YA, et al. Study of normal human serum proteomic profile under conditions of hyperbaric oxygen-nitrogen-argon exposure. *Bull Exp Biol Med* 2010; 149: 37–39.
72. Walker BR, Hong SK, Mookerjee BK, et al. Suppressed renin release during hyperoxia in the conscious dog. *Undersea Biomed Res* 1981; 8: 137–145.
73. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pr* 2014; 103: 137–149.
74. Schnell O, Cappuccio F, Genovese S, et al. Type 1 diabetes and cardiovascular disease. *Cardiovasc Diabetol* 2013; 12: 156.